ArticlePediatric research2026
Growth hormone treatment in cerebral palsy: long-term impact on growth, outcomes, and complications.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examined the effects of growth hormone (GH) treatment on growth and metabolic parameters, gross motor function, and musculoskeletal complications in children with cerebral palsy.
methodsThis retrospective single-center study included children who received GH treatment for over 1 year. Data on growth-related variables, metabolic indicators, and disease-specific factors were collected. Statistical analyses examined associations between GH treatment duration and outcomes, with pre- and post-treatment comparisons.
resultsTwenty-two patients were enrolled in this study. GH treatment significantly improved height and weight Z-scores, along with insulin-like growth factor-1 Z-scores, regardless of GH deficiency or ambulatory status. Metabolic changes significantly included an increased bone age-to-chronological age ratio, decreased aspartate aminotransferase levels, and elevated uric acid levels. The gross motor function did not decline, and there was no significant worsening of hip subluxation or scoliosis.
conclusionGH treatment led to significant improvements in growth and metabolic-related parameters without adverse effects on gross motor function or musculoskeletal complications. These findings suggest that GH treatment may be a safe and effective treatment option for children with cerebral palsy, providing potential benefits without increasing the risk of orthopedic complications. IMPACT: This study is the first to assess the long-term effects of GH treatment in children with CP. GH treatment improved height, weight, and insulin-like growth factor-1 Z-scores. Gross motor function did not decline during treatment, and no significant worsening of hip subluxation or scoliosis detected. There is a lack of longitudinal studies on the long-term effects of growth hormone administration in children with CP. It is anticipated that this study will lay the groundwork for large-scale multicenter prospective research.
Indexed as
Identifiers
41028509What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.